Sign In
Buy IMTX
$10.21
+0.165 (+1.64%)
At Close: Jun 03, 2026
Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?
01:33pm, Thursday, 10'th Oct 2024
On Thursday, Immatics N.V. IMTX stock is trading lower after the company commenced an underwritten public offering of $150 million.
Immatics Announces Proposed $150 Million Public Offering
07:30am, Thursday, 10'th Oct 2024
Houston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-r
Company to host conference call and webcast today, October 10, at 9:00 am EDT/3:00 pm CEST
Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024
09:00am, Friday, 04'th Oct 2024
Houston, Texas and Tuebingen, Germany, October 4, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and dev
Houston, Texas and Tuebingen, Germany, September 16, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and
Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
07:00am, Friday, 06'th Sep 2024
Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
09:11am, Tuesday, 13'th Aug 2024
Immatics (IMTX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.35 per share a year ago.
Immatics Announces Second Quarter 2024 Financial Results and Business Update
07:00am, Tuesday, 13'th Aug 2024
Houston, Texas and Tuebingen, Germany, August 13, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and dev
Wall Street Analysts Predict a 54.95% Upside in Immatics (IMTX): Here's What You Should Know
11:00am, Monday, 22'nd Jul 2024
The consensus price target hints at a 55% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Here's Why 'Trend' Investors Would Love Betting on Immatics (IMTX)
09:51am, Monday, 22'nd Jul 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Immatics (IMTX) could be a great choice. It is one of the several stocks that passed through our "Recent Price
Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates
09:16am, Tuesday, 14'th May 2024
Immatics (IMTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.28 per share a year ago.
Immatics Announces First Quarter 2024 Financial Results and Business Update
07:00am, Tuesday, 14'th May 2024
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME
Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case
10:32am, Saturday, 27'th Apr 2024
Immatics, a German biotech company, achieved its Nasdaq listing in 2020 through a merger with Arya Sciences Acquisition Corp, a SPAC sponsored by Perceptive Advisors. The company focuses on developing
Immatics Announces Full Year 2023 Financial Results and Corporate Update
07:00am, Thursday, 21'st Mar 2024
Houston, Texas and Tuebingen, Germany, March 21, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-red
Immatics: Pioneering TCR Therapies In The Fight Against Cancer
07:56am, Saturday, 03'rd Feb 2024
Immatics is a significant player in T-cell redirecting cancer immunotherapies, with a clinical-stage pipeline showing promising interim results. The company has formed strategic partnerships with Mode
